| Domain | Summary | Evidence type | Key citations |
|---|---|---|---|
| Definition | PRR12-related neuroocular syndrome is a newly delineated Mendelian developmental disorder caused by PRR12 haploinsufficiency, characterized chiefly by developmental impairment/intellectual disability with variable structural and functional eye abnormalities plus multisystem involvement. | Observed human cohort evidence | (pqac-00000009, pqac-00000000) |
| Evidence cohort | Disease-defining cohort: 24 individuals total, including 3 previously reported and 21 newly added; sex distribution 11 female/13 male; age range 5 months-36 years. Four additional DECIPHER individuals with de novo PRR12 variants and one additional DECIPHER microdeletion involving PRR12 were noted as supportive evidence. | Observed human cohort evidence | (pqac-00000009, pqac-00000019, pqac-00000016) |
| Inheritance | Variants were de novo when parental testing/sequencing was possible; pattern is consistent with autosomal dominant disease due to haploinsufficiency. No established evidence for recessive inheritance, anticipation, or founder effect. | Observed human cohort evidence with interpretation | (pqac-00000019, pqac-00000000) |
| Gene / variant mechanism | PRR12 encodes a 211-kDa nuclear protein with suspected DNA-binding activity. In the 24-patient cohort: 12 frameshift, 6 nonsense, 1 splice-site, 2 missense variants, and 1 gross deletion involving PRR12. Truncating/splice variants are predicted loss-of-function via nonsense-mediated decay; the overall disease mechanism is haploinsufficiency. Two de novo missense variants were predicted damaging in silico: c.3505C>T (p.Arg1169Trp) and c.5909T>C (p.Leu1970Pro). PRR12 is highly constrained for loss-of-function variation (pLI 1.00; o/e 0.0, 90% CI 0-0.05; LOEUF 0.051). | Observed human genetic evidence; some mechanistic prediction | (pqac-00000009, pqac-00000016, pqac-00000000) |
| Core phenotype frequencies | Developmental impairment: all sequence-variant cases described; among 23 with sequence variants, 17 global developmental delay, 3 isolated motor delay, 4 isolated speech-language delay. Intellectual disability documented in all 11/11 individuals older than 7 years with available data. Structural eye defects in 12/24 (50%). Globe defects/anophthalmia or microphthalmia in 4/24 (16.7%), observed only in females in this cohort. Coloboma in 7/24 (29%). Visual impairment in 17/22 (77%). Strabismus in 8/22 (36%). | Observed human cohort evidence | (pqac-00000019, pqac-00000015, pqac-00000003) |
| Other systemic frequencies | Hypotonia 14/23 (61%). Congenital heart defects 12/23 (52%) including atrial septal defects (6), ventricular septal defects (2), pulmonary stenosis (3), with one patient having two defects. Kidney anomalies 8/23 (35%), including hydronephrosis, duplicated ureters, and vesicoureteral reflux. Failure to thrive 13/24 (54%). Microcephaly 7/24 (29%). Cleft palate 4/24 (17%). Intestinal malrotation 2/24 (8%). Meckel diverticulum 1/24 (4%). Cryptorchidism 5/13 males (38%). | Observed human cohort evidence | (pqac-00000015, pqac-00000012, pqac-00000018) |
| Expression / mechanism | Observed: PRR12 is ubiquitously expressed, with highest levels reported in brain (especially cerebellum/pituitary), thyroid, and female reproductive tissues; protein is nuclear-localized; fetal mouse and fetal human brain expression exceeds adult brain expression. PRR12 is associated with poised chromatin regions in embryonic/iPSC/neural progenitor contexts. Hypothesis: PRR12 likely functions in early neurodevelopment and transcriptional/chromatin regulation, possibly involving AT-hook-mediated DNA binding and networks enriched for transcription factors, chromatin regulators, SET-domain proteins, bromodomain proteins, and candidate interactors such as USP7, SOX2, and ESR2; these interactions remain unproven experimentally. | Mixed: observed expression/bioinformatic evidence; mechanistic hypotheses clearly labeled | (pqac-00000014, pqac-00000008, pqac-00000004) |
| Diagnosis | Current diagnosis is gene-first and molecular, typically via exome/genome sequencing or other broad genomic testing, supported by the recurrent phenotype of developmental impairment plus variable ocular anomalies. A PRR12-containing microdeletion can also support diagnosis. Ophthalmologic evaluation is important because some posterior-chamber defects may be missed on physical exam; incomplete eye assessments were a study limitation. ClinVar submissions were reported for several variants. | Observed human cohort evidence with practical diagnostic implication | (pqac-00000009, pqac-00000015, pqac-00000008) |
| Management | No disease-specific therapy or standardized treatment algorithm was established in the evidence reviewed. Management is supportive and phenotype-directed in practice, especially developmental services and organ-system evaluation (ophthalmology, cardiology, nephrology) based on observed multisystem involvement; however, explicit surveillance guidelines were not provided in the paper. | Evidence gap / limited inference from observed phenotype | (pqac-00000009, pqac-00000015, pqac-00000018) |
| Epidemiology | Prevalence and incidence are not established. Evidence consists of rare case aggregation and database-supported cases. PRR12 loss-of-function variants are extremely rare in population databases, supporting rarity and intolerance to haploinsufficiency. | Observed rarity / evidence gap | (pqac-00000009, pqac-00000000) |
| Trials / therapies | No relevant interventional clinical trials were identified in the available search results. No gene therapy, RNA therapy, or targeted therapy specific to PRR12-related neuroocular syndrome was established in the available evidence. | Evidence gap | (pqac-00000009) |
| Key limitations | Phenotypic variability is substantial. Three individuals had additional genetic findings that could confound attribution. Some ophthalmologic evaluations were incomplete. Genotype-phenotype correlation remains uncertain, especially regarding isoform-specific effects. Functional evidence is limited mainly to expression/bioinformatic data; animal-model validation and mechanistic studies were explicitly called for. | Observed study limitations and explicit author uncertainty | (pqac-00000015, pqac-00000008, pqac-00000014) |


*Table: This table condenses the current disease-defining evidence for PRR12-related neuroocular syndrome into knowledge-base-ready fields. It separates observed human findings from mechanistic hypotheses and highlights where evidence is still lacking.*